source
- Roche reports superior survival for KRAS G12C inhibitor divarasib in phase 3 trialRoche presented detailed results from its phase 3 Krascendo 1 trial of the KRAS G12C inhibitor divarasib, comparing it with Amgen’s Lumakras and Bristol Myers Squibb’s Krazati. The open‑label stud…
- Merck and Moderna disclose phase 3 cancer vaccine data early after leak, showing improved recurrence-free survival with KeytrudaMerck & Co. and Moderna were forced to release their phase 3 trial results for the intismeran autogene cancer vaccine two days ahead of schedule after an unexpected leak of the data ahead of the ES…Fierce Biotech · 17d agoPositive readoutNeutral